Integrin activation to augment sars-COV-2 vaccination

Ended Project Grant Awarded Last action

Award ID
R43AI162169
Recipient
Awarding agency
Obligated
$893,172

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date
Funding
  • $595,448.00 Federal
  • $297,724.00 Non-federal
Place of performance
Texas, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
On march 11, 2020 the world health organization (who) announced a global coronavirus disease 2019 (covid-19) pandemic. The disease is characterized by severe flu-like symptoms, with advanced age (>65 years) an important risk factor for sars-COV-2-induced death. Current clinical stage COV-2 vaccine programs must include this important and vulnerable population in their initial testing, and generate rapid antibody and cellular specific responses to combat disease. Integrin activating compounds are immune modulators that can potentiate productive responses to vaccine antigens; our preliminary data gives US strong confidence they may be similarly effective in enhancing effectiveness of a coronavirus (covid-19) vaccine, especially in aged populations. This study will directly test the hypothesis that a novel, proprietary integrin activator (7HP349) delivered with the sars-COV-2 spike protein (RBD containing domain) vaccine candidate will generate high titer neutralizing antibodies that will yield protective outcome (neutralization) post challenge with viral agents. Our premise is that 7HP349 can be used as oral immune activator to augment systemic immunity of vaccines as a prophylactic tool to control spread of sars-COV-2. IT is furthermore envisioned to be used with an existing vaccine without requiring antigen reformulation. Our ultimate goal is to ameliorate coronavirus burden and subsequent covid-19 disease in both adult and aged individuals.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $297,724 $0
Original award $297,724 $297,724

Quick answers

Who received award R43AI162169?

R43AI162169 was awarded to 7 Hills Pharma Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 1, 2021.

How much is award R43AI162169 worth?

$893,172 has been obligated on R43AI162169: $595,448 in federal funding and $297,724 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login